Tweet
Clin Vaccine Immunol. 2012 Feb 29. [Epub ahead of print]
Long-term Immunogenicity of the Pandemic Influenza A/H1N1 2009 Vaccine in Adults: MF59 Adjuvanted Vaccine versus Unadjuvanted Vaccine.
Song JY, Cheong HJ, Seo YB, Kim IS, Noh JY, Heo JY, Choi WS, Lee J, Kim WJ.
Source
Division of Infectious Diseases, Department of Internal Medicine, Korea University College of Medicine, Seoul, Korea.
Abstract
Since the first reports of the A/H1N1 virus in April 2009, the pandemic influenza spread globally and circulated for a long time. The primary method for the control of influenza is vaccination, but levels of influenza vaccine-induced antibody are known to decline rapidly over a sixth-month period. In adults aged 18-64 years, we compared the long-term immunogenicity of two of the influenza A/H1N1 2009 monovalent vaccines: 3.75 μg MF59 adjuvanted vaccine versus 15 μg unadjuvanted vaccine. The serum hemagglutinin inhibition (HI) titers were determined pre-vaccination and at one, six, and ten months after vaccination. One hundred and six (88.3%) of the 120 subjects were followed for the entire ten-month period after receiving the influenza A/H1N1 2009 monovalent vaccine. There were 60 patients who received the unadjuvanted vaccine and 46 patients who received the MF59 adjuvanted vaccine. The seroprotection rates, seroconversion rates, and the GMT folds fulfilled the criteria of the European Medicines Agency (EMA) for influenza A/California/7/2009 (H1N1) at one month after vaccination irrespective of the vaccine composition. Although the one month post-vaccination GMTs were somewhat higher in the unadjuvanted vaccine recipients compared to the MF59 adjuvanted vaccine recipients, the difference was not significant (p=0.29). The seroprotection rates at six and ten months post-vaccination were preserved above 70%, but only in the MF59 adjuvanted vaccine recipients. In conclusion, Low-dose MF59 adjuvanted influenza vaccine even with 3.75 μg hemagglutinin antigen might induce excellent long-term immunity comparable to the conventional-dose of unadjuvanted vaccine among healthy adults aged 18-64 years.
PMID:
22379067
[PubMed - as supplied by publisher]
Long-term Immunogenicity of the Pandemic Influenza A/H1N1 2009 Vaccine in Adults: MF59 Adjuvanted Vaccine versus Unadjuvanted Vaccine.
Song JY, Cheong HJ, Seo YB, Kim IS, Noh JY, Heo JY, Choi WS, Lee J, Kim WJ.
Source
Division of Infectious Diseases, Department of Internal Medicine, Korea University College of Medicine, Seoul, Korea.
Abstract
Since the first reports of the A/H1N1 virus in April 2009, the pandemic influenza spread globally and circulated for a long time. The primary method for the control of influenza is vaccination, but levels of influenza vaccine-induced antibody are known to decline rapidly over a sixth-month period. In adults aged 18-64 years, we compared the long-term immunogenicity of two of the influenza A/H1N1 2009 monovalent vaccines: 3.75 μg MF59 adjuvanted vaccine versus 15 μg unadjuvanted vaccine. The serum hemagglutinin inhibition (HI) titers were determined pre-vaccination and at one, six, and ten months after vaccination. One hundred and six (88.3%) of the 120 subjects were followed for the entire ten-month period after receiving the influenza A/H1N1 2009 monovalent vaccine. There were 60 patients who received the unadjuvanted vaccine and 46 patients who received the MF59 adjuvanted vaccine. The seroprotection rates, seroconversion rates, and the GMT folds fulfilled the criteria of the European Medicines Agency (EMA) for influenza A/California/7/2009 (H1N1) at one month after vaccination irrespective of the vaccine composition. Although the one month post-vaccination GMTs were somewhat higher in the unadjuvanted vaccine recipients compared to the MF59 adjuvanted vaccine recipients, the difference was not significant (p=0.29). The seroprotection rates at six and ten months post-vaccination were preserved above 70%, but only in the MF59 adjuvanted vaccine recipients. In conclusion, Low-dose MF59 adjuvanted influenza vaccine even with 3.75 μg hemagglutinin antigen might induce excellent long-term immunity comparable to the conventional-dose of unadjuvanted vaccine among healthy adults aged 18-64 years.
PMID:
22379067
[PubMed - as supplied by publisher]
